These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 22652566)

  • 21. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.
    Heinrich MC; Corless CL; Blanke CD; Demetri GD; Joensuu H; Roberts PJ; Eisenberg BL; von Mehren M; Fletcher CD; Sandau K; McDougall K; Ou WB; Chen CJ; Fletcher JA
    J Clin Oncol; 2006 Oct; 24(29):4764-74. PubMed ID: 16954519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DDR1/2 enhance KIT activation and imatinib resistance of primary and secondary KIT mutants in gastrointestinal stromal tumors.
    Liu A; Zhang S; Wang M; Zhang L; Xu S; Nasimian A; Li S; Zhao S; Cao X; Tian J; Yu Y; Fan Z; Xiao K; Zhao H; Kazi JU; Ma L; Sun J
    Mol Carcinog; 2024 Jan; 63(1):75-93. PubMed ID: 37737519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.
    Agaram NP; Wong GC; Guo T; Maki RG; Singer S; Dematteo RP; Besmer P; Antonescu CR
    Genes Chromosomes Cancer; 2008 Oct; 47(10):853-9. PubMed ID: 18615679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
    Italiano A; Bui B
    Bull Cancer; 2008 Jan; 95(1):107-16. PubMed ID: 18230576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
    Cohen NA; Zeng S; Seifert AM; Kim TS; Sorenson EC; Greer JB; Beckman MJ; Santamaria-Barria JA; Crawley MH; Green BL; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Cancer Res; 2015 May; 75(10):2061-70. PubMed ID: 25836719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
    Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
    Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes.
    Burger H; den Bakker MA; Kros JM; van Tol H; de Bruin AM; Oosterhuis W; van den Ingh HF; van der Harst E; de Schipper HP; Wiemer EA; Nooter K
    Cancer Biol Ther; 2005 Nov; 4(11):1270-4. PubMed ID: 16294026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.
    Zhao J; Quan H; Xu Y; Kong X; Jin L; Lou L
    Cancer Sci; 2014 Jan; 105(1):117-25. PubMed ID: 24205792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth.
    Edris B; Willingham SB; Weiskopf K; Volkmer AK; Volkmer JP; Mühlenberg T; Montgomery KD; Contreras-Trujillo H; Czechowicz A; Fletcher JA; West RB; Weissman IL; van de Rijn M
    Proc Natl Acad Sci U S A; 2013 Feb; 110(9):3501-6. PubMed ID: 23382202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiple intratumoral sources of kit ligand promote gastrointestinal stromal tumor.
    Tieniber AD; Rossi F; Hanna AN; Liu M; Etherington MS; Loo JK; Param N; Zeng S; Do K; Wang L; DeMatteo RP
    Oncogene; 2023 Aug; 42(34):2578-2588. PubMed ID: 37468679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KIT mutations in GIST.
    Fletcher JA; Rubin BP
    Curr Opin Genet Dev; 2007 Feb; 17(1):3-7. PubMed ID: 17208434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo effect of imatinib on progression of cecal GIST-like tumors in exon 17-type c-kit knock-in mice.
    Ishikawa T; Nakai N; Liu NN; Shiba K; Isozaki K; Matsuda I; Ito T; Fujimoto J; Hatakeyama K; Kanda T; Hirota S
    Lab Invest; 2009 Oct; 89(10):1161-8. PubMed ID: 19636292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.
    Antonescu CR; Besmer P; Guo T; Arkun K; Hom G; Koryotowski B; Leversha MA; Jeffrey PD; Desantis D; Singer S; Brennan MF; Maki RG; DeMatteo RP
    Clin Cancer Res; 2005 Jun; 11(11):4182-90. PubMed ID: 15930355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor.
    Rossi F; Ehlers I; Agosti V; Socci ND; Viale A; Sommer G; Yozgat Y; Manova K; Antonescu CR; Besmer P
    Proc Natl Acad Sci U S A; 2006 Aug; 103(34):12843-8. PubMed ID: 16908864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate.
    Liu Y; Tseng M; Perdreau SA; Rossi F; Antonescu C; Besmer P; Fletcher JA; Duensing S; Duensing A
    Cancer Res; 2007 Mar; 67(6):2685-92. PubMed ID: 17363589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The V654A second-site KIT mutation increases tumor oncogenesis and STAT activation in a mouse model of gastrointestinal stromal tumor.
    Zhang JQ; Bosbach B; Loo JK; Vitiello GA; Zeng S; Seifert AM; Medina BD; Param NJ; Maltbaek JH; Rossi F; Antonescu CR; Besmer P; DeMatteo RP
    Oncogene; 2020 Dec; 39(49):7153-7165. PubMed ID: 33024275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gastrointestinal stromal tumor: a bridge between bench and bedside.
    Nishida T; Takahashi T; Miyazaki Y
    Gastric Cancer; 2009; 12(4):175-88. PubMed ID: 20047122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).
    Lasota J; Miettinen M
    Semin Diagn Pathol; 2006 May; 23(2):91-102. PubMed ID: 17193822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SPRY4 inhibits and sensitizes the primary KIT mutants in gastrointestinal stromal tumors (GISTs) to imatinib.
    Li S; Zhao S; Liang N; Zhang S; Zhang L; Zhou L; Liu A; Cao X; Tian J; Yu Y; Fan Z; Xiao K; Wang M; Zhao H; Bai R; Sun J
    Gastric Cancer; 2023 Sep; 26(5):677-690. PubMed ID: 37222910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.
    Smyth T; Van Looy T; Curry JE; Rodriguez-Lopez AM; Wozniak A; Zhu M; Donsky R; Morgan JG; Mayeda M; Fletcher JA; Schöffski P; Lyons J; Thompson NT; Wallis NG
    Mol Cancer Ther; 2012 Aug; 11(8):1799-808. PubMed ID: 22714264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.